Cityscape tigit trial
WebMay 14, 2024 · Basel, 14 May 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive results from the Phase II CITYSCAPE trial, the first randomised … WebDec 10, 2024 ·
Cityscape tigit trial
Did you know?
WebTiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Abstract: Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when ... WebMay 29, 2024 · The 2024 annual meeting of the American Society of Clinical Oncology that launches today will feature the first results from CITYSCAPE, a trial involving a novel immunotherapy approach in non-small cell lung cancer (NSCLC). This phase 2 trial is the first to combine the immunotherapy tiragolumab with atelzolizumab (Tecentriq), the …
WebMay 25, 2024 · Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as … WebJan 5, 2024 · Small cell lung cancer (SCLC) is characterized by rapid progression and poor prognosis. Although the phase II CITYSCAPE-02 trial found objective response rate (ORR) and progression-free survival (PFS) of non-small cell lung cancer (NSCLC) patients improved when tiragolumab was added to atezolizumab and chemotherapy, the phase III …
WebDec 10, 2024 · CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer … WebDec 10, 2024 · South San Francisco, CA -- December 10, 2024 --. Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new follow-up …
WebMar 30, 2024 · The phase 3 trial, dubbed SKYSCRAPER-02, evaluated the investigational anti-TIGIT immunotherapy tiragolumab plus Tecentriq (atezolizumab) and chemotherapy (carboplatin and etoposide) as an initial ...
WebDec 10, 2024 · CITYSCAPE is the first randomised phase II trial of an anti-TIGIT therapy and is investigating tiragolumab in PD-L1-positive metastatic non-small cell lung cancer … twix easy drawingWebJan 4, 2024 · CITYSCAPE is the first randomized, phase 2 study of an anti-TIGIT antibody. The trial enrolled treatment-naïve patients with stage IV NSCLC who had EGFR or ALK … twix factory tourWebBased on the CITYSCAPE data, researchers have now launched the Phase III SKYSCRAPER trial in NSCLC patients with PD-L1 scores of 50 percent or higher. In reviewing the data from the Phase Ia/Ib trial, Michele Teng from the QIMR Berghofer Medical Research Institute discussed additional predictive markers that researchers … talent financial snyder txWebJun 1, 2024 · CITYSCAPE is a randomized phase 2 trial. We enrolled 135 patients. Patients were newly diagnosed with metastatic non—small cell lung cancer. They were negative … talentfind solutionsWebJun 17, 2024 · The CITYSCAPE trial is a randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab atezolizumab vs placebo atezolizumab in patients with PD-L1-selected NSCLC. Dr Johnson outlines the trial design, promising results and future prospects of the CITYSCAPE study. twix extra large egg 328gWebMay 12, 2024 · The phase 3 SKYSCRAPER-01 study (NCT04294810) evaluating the addition of tiragolumab to atezolizumab (Tecentriq) as first-line treatment for people with PD-L1-high, locally advanced or metastatic non-small cell lung cancer (NSCLC) did not meet its co-primary end point of progression-free survival (PFS), according to Roche. 1 This first … talent finance innovation networkWebJun 23, 2024 · The most mature prospective trial data available for the use of anti-TIGIT agents for patients with stage IV NSCLC is for the drug tiragolumab, used in the phase 2 CITYSCAPE trial. The CITYSCAPE … twix facts